Released on August 27, 2016

Genomics has been used with varying degrees of success in the context of drug discovery and in defining mechanisms of action for diseases like cancer and neurodegenerative and rare diseases in the quest for orphan drugs. To improve its utility, accuracy, and cost-effectiveness optimization of...

Released on June 09, 2016

For patients with ulcerative colitis, the most common form of inflammatory bowel disease (IBD), aminosalicylates such as mesalamine provide first-line anti-inflammatory therapy.  As efficacy is related to tissue concentration, when administered as a rectal enema, lack of retention...

Released on May 26, 2016

The importance of treatment-related side effects in impeding effective cancer therapy was recognized in the recently articulated “cancer moonshot” initiative. Regimen-related toxicities impact the overall success of treatment outcomes—in some sense, a tail capable of wagging the dog. To truly...

Released on April 16, 2016

Oral mucositis (OM) is among the most common, painful, and debilitating toxicities of cancer regimen-related treatment, resulting in the formation of ulcers, which are susceptible to increased colonization of microorganisms. Novel discoveries in OM have focused on understanding the host-...

Released on April 06, 2016

We have characterized a novel 21 amino acid-peptide derived from Antrum Mucosal Protein (AMP)-18 that mediates growth promotion of cultured normal epithelial cells and mitigates radiation-induced oral mucositis in animal models, while suppressing in vitro function of cancer cells. The objective...

Released on March 15, 2016

The association between chronic inflammatory disorders and oral carcinogenesis has been both a source of interest and contention. Based upon its central importance in oral carcinogenesis, the finding that the PI3k/Akt/mTOR pathway is activated in oral lichen planus, chronic graft-versus-host...

Released on February 03, 2016

Low level laser therapy (LLLT) has been noted to be effective in mitigating the development of oral mucositis among patients being treated with chemoradiation for cancers of the head and neck. To explain the biological basis for this observation we performed a comprehensive literature search....

Released on September 15, 2015

Gastrointestinal toxicities (GIT), including oral mucositis, nausea and vomiting, and diarrhea, are common side effects of chemotherapy and targeted agents in patients with advanced colorectal cancer and pancreatic cancer. Being often underreported, it is still difficult to precisely establish...

Released on May 01, 2015

The successes of the Human Genome Project catalyzed the transition of genomics from the laboratory to the clinic. Over the past decade, there has been a proliferation of studies demonstrating the potential utility of various applications of genomics as a conduit to accelerate drug development,...

Released on May 01, 2015

Purpose of Review: Oral mucositis remains a frequent debilitating toxicity associated with drug and radiation regimens used to treat cancer. This review highlights the recent understanding of the biological basis, risk factors for, and management for oral mucositis. Recent Findings: Prevalence...